ZIM
MYGN icon

Zacks Investment Management’s Myriad Genetics MYGN Stock Holding History

Zacks Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,351
Closed -$476K – 595
2019
Q1 		$476K Buy
+14,351
New +$437K 0.01% 459
2016
Q4 		– Sell
-13,256
Closed -$273K – 698
2016
Q3 		$273K Buy
+13,256
New +$336K 0.01% 515
2014
Q3 		– Sell
-11,054
Closed -$430K – 720
2014
Q2 		$430K Buy
+11,054
New +$411K 0.02% 483
2013
Q4 		– Sell
-16,088
Closed -$378K – 715
2013
Q3 		$378K Sell
16,088
-854
-5% -$24.3K 0.02% 441
2013
Q2 		$455K Buy
+16,942
New +$491K 0.02% 327

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Zacks Investment Management's MYGN Position: Q2 2019 in Review

Zacks Investment Management sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 14,351 shares — an estimated $476K sold.

Zacks Investment Management first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $476K in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Zacks Investment Management reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Zacks Investment Management sold 14,351 Myriad Genetics shares in Q2 2019, an estimated $476K.
  • Zacks Investment Management first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
  • Zacks Investment Management's Myriad Genetics position peaked at $476K in Q1 2019.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Zacks Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.